These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17651968)

  • 1. Synthesis and structure-activity relationship of novel RXR antagonists: orally active anti-diabetic and anti-obesity agents.
    Sakaki J; Kishida M; Konishi K; Gunji H; Toyao A; Matsumoto Y; Kanazawa T; Uchiyama H; Fukaya H; Mitani H; Arai Y; Kimura M
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4804-7. PubMed ID: 17651968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of orally efficacious benzimidazoles as melanin-concentrating hormone receptor 1 antagonists.
    Wu WL; Burnett DA; Caplen MA; Domalski MS; Bennett C; Greenlee WJ; Hawes BE; O'Neill K; Weig B; Weston D; Spar B; Kowalski T
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3674-8. PubMed ID: 16690315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of some novel isochroman carboxylic acid derivatives as potential anti-diabetic agents.
    Lakshminarayana N; Rajendra Prasad Y; Gharat L; Thomas A; Ravikumar P; Narayanan S; Srinivasan CV; Gopalan B
    Eur J Med Chem; 2009 Aug; 44(8):3147-57. PubMed ID: 19349096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel substituted aminoalkylguanidines as potential antihyperglycemic and food intake-reducing agents.
    Tassoni E; Giannessi F; Brunetti T; Pessotto P; Renzulli M; Travagli M; Rajamäki S; Prati S; Dottori S; Corelli F; Cabri W; Carminati P; Botta M
    J Med Chem; 2008 Jun; 51(11):3073-6. PubMed ID: 18465847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of benzofused heterocyclic RXR modulators.
    Gernert DL; Neel DA; Boehm MF; Leibowitz MD; Mais DA; Michellys PY; Rungta D; Reifel-Miller A; Grese TA
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2759-63. PubMed ID: 15125928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel orally active ureido NPY Y5 receptor antagonists.
    Li G; Stamford AW; Huang Y; Cheng KC; Cook J; Farley C; Gao J; Ghibaudi L; Greenlee WJ; Guzzi M; van Heek M; Hwa JJ; Kelly J; Mullins D; Parker EM; Wainhaus S; Zhang X
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1146-50. PubMed ID: 18160282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of substituted quinolines as novel and selective melanin concentrating hormone antagonists as anti-obesity agents.
    Warshakoon NC; Sheville J; Bhatt RT; Ji W; Mendez-Andino JL; Meyers KM; Kim N; Wos JA; Mitchell C; Paris JL; Pinney BB; Reizes O; Hu XE
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5207-11. PubMed ID: 16870427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of 5,5-diphenylimidazolones as potent human neuropeptide Y5 receptor antagonists.
    Gillman KW; Higgins MA; Poindexter GS; Browning M; Clarke WJ; Flowers S; Grace JE; Hogan JB; McGovern RT; Iben LG; Mattson GK; Ortiz A; Rassnick S; Russell JW; Antal-Zimanyi I
    Bioorg Med Chem; 2006 Aug; 14(16):5517-26. PubMed ID: 16697206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent and orally active MTP inhibitors as potential anti-obesity agents.
    Li J; Bertinato P; Cheng H; Cole BM; Bronk BS; Jaynes BH; Hickman A; Haven ML; Kolosko NL; Barry CJ; Manion TB
    Bioorg Med Chem Lett; 2006 Jun; 16(11):3039-42. PubMed ID: 16529928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Derivatives of 1,4-bis(3-hydroxycarbonyl-4-hydroxyl)styrylbenzene as PTP1B inhibitors with hypoglycemic activity.
    Shrestha S; Bhattarai BR; Kafle B; Lee KH; Cho H
    Bioorg Med Chem; 2008 Sep; 16(18):8643-52. PubMed ID: 18722777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substituted 1,2,3,4-tetrahydroquinolin-6-yloxypropanes as beta3-adrenergic receptor agonists: design, synthesis, biological evaluation and pharmacophore modeling.
    Shakya N; Roy KK; Saxena AK
    Bioorg Med Chem; 2009 Jan; 17(2):830-47. PubMed ID: 19081260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mono- and disalicylic acid derivatives: PTP1B inhibitors as potential anti-obesity drugs.
    Shrestha S; Bhattarai BR; Lee KH; Cho H
    Bioorg Med Chem; 2007 Oct; 15(20):6535-48. PubMed ID: 17692525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists.
    Suzuki T; Kameda M; Ando M; Miyazoe H; Sekino E; Ito S; Masutani K; Kamijo K; Takezawa A; Moriya M; Ito M; Ito J; Nakase K; Matsushita H; Ishihara A; Takenaga N; Tokita S; Kanatani A; Sato N; Fukami T
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5339-45. PubMed ID: 19683441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
    Michellys PY; Ardecky RJ; Chen JH; Crombie DL; Etgen GJ; Faul MM; Faulkner AL; Grese TA; Heyman RA; Karanewsky DS; Klausing K; Leibowitz MD; Liu S; Mais DA; Mapes CM; Marschke KB; Reifel-Miller A; Ogilvie KM; Rungta D; Thompson AW; Tyhonas JS; Boehm MF
    J Med Chem; 2003 Jun; 46(13):2683-96. PubMed ID: 12801232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents.
    Lakshminarayana N; Prasad YR; Gharat L; Thomas A; Narayanan S; Raghuram A; Srinivasan CV; Gopalan B
    Eur J Med Chem; 2010 Sep; 45(9):3709-18. PubMed ID: 20627471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
    Michellys PY; Ardecky RJ; Chen JH; D'Arrigo J; Grese TA; Karanewsky DS; Leibowitz MD; Liu S; Mais DA; Mapes CM; Montrose-Rafizadeh C; Ogilvie KM; Reifel-Miller A; Rungta D; Thompson AW; Tyhonas JS; Boehm MF
    J Med Chem; 2003 Sep; 46(19):4087-103. PubMed ID: 12954061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of lipophilicity at the lipophilic domain of RXR agonists enables production of subtype preference: RXRalpha-preferential agonist possessing a sulfonamide moiety.
    Takamatsu K; Takano A; Yakushiji N; Morishita K; Matsuura N; Makishima M; Ali HI; Akaho E; Tai A; Sasaki K; Kakuta H
    ChemMedChem; 2008 Mar; 3(3):454-60. PubMed ID: 18157857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel thioamide derivatives as neutral CB1 receptor antagonists.
    Boström J; Olsson RI; Tholander J; Greasley PJ; Ryberg E; Nordberg H; Hjorth S; Cheng L
    Bioorg Med Chem Lett; 2010 Jan; 20(2):479-82. PubMed ID: 20005704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydro-[1H]-quinolin-2-ones as retinoid X receptor (RXR) agonists for potential treatment of dyslipidemia.
    Lagu B; Lebedev R; Pio B; Yang M; Pelton PD
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3491-6. PubMed ID: 17490875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors.
    Onda K; Shiraki R; Ogiyama T; Yokoyama K; Momose K; Katayama N; Orita M; Yamaguchi T; Furutani M; Hamada N; Takeuchi M; Okada M; Ohta M; Tsukamoto S
    Bioorg Med Chem; 2008 Dec; 16(23):10001-12. PubMed ID: 18952447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.